# Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

> **NCT04030533** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Guselkumab (SC): Dose 1
- **DRUG:** Guselkumab (SC): Dose 2
- **DRUG:** Guselkumab (IV): Dose 1
- **DRUG:** Guselkumab (IV): Dose 2
- **DRUG:** Ustekinumab 6 mg/mL

## Key facts

- **NCT ID:** NCT04030533
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-29
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04030533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04030533, "Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04030533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*